JAK1 and prostate cancer: However, a recent study confirmed that combined inhibition of the JAK1-2/STAT-3 pathway and PD-L1 blockade decreases the escape of CRPC cells from the cytotoxic action of NK cells under hypoxic conditions [60], indicating the importance of implementing STAT-3 inhibitors in combination with blockers directed against highly expressed targets in prostate cancer.